European Notebook: A Smooth Succession At Roche, EMA’s New Leadership Team, A Medicine Bank In Greece, Atorvastatin Price Drop In Ireland
Executive Summary
Lufthansa's Christoph Franz will become Roche’s chairman next year; more restructuring details emerge from the European Medicines Agency; pharma companies donate medicines in Greece; Ireland names preferred medicines and aims to cut atorvastatin price.
You may also be interested in...
EMA’s Heralded Revamp May Be Hampered By Tight Budget And Staffing
The EMA has announced a major restructuring plan to better aid its stakeholders, but tight staffing levels and budget stagnation could hamper the effort.
German Drug Report Could Mean More Pressure On Pharma Revenues
The annual German prescription report suggests an additional €4.6 billion can be cut from the country’s annual drug expenditures, which could cause the government to extend its temporary price moratorium and mandatory rebate, as well as pursue other cost-cutting measures.
European Notebook: AstraZeneca Snuggles Up To Potential Partners In New Cambridge HQ, Viagra Patents Expire In Europe
AstraZeneca's new HQ is to cornerstone a growing U.K. cluster of clinical and research assets; the EU and U.S. start talks on what could be the world's largest free trade agreement; Viagra patent expiry provides a lift for European generic companies; European wholesalers support the liquidity of European health care markets; new pricing system for generics in Ireland.